Review
Cell & Tissue Engineering
Yajing Wang, Dan Ma, Zewen Wu, Baoqi Yang, Rong Li, Xingxing Zhao, Helin Yang, Liyun Zhang
Summary: Mesenchymal stem cells have great application value in cell replacement therapy and tissue repair, and their application in the treatment of rheumatic diseases is receiving increasing attention. These cells have the ability to differentiate into various cell types and are involved in immune regulation, inflammation alleviation, anti-fibrotic properties, and vascular repair.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Biochemistry & Molecular Biology
Bong-Woo Lee, Seung-Ki Kwok
Summary: Systemic rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, are chronic autoimmune diseases affecting multiple organs and tissues. Mesenchymal stem/stromal cell (MSC)-based therapy shows promise for treating these diseases due to the regenerative and immunomodulatory properties of MSCs. However, there are challenges related to MSC sourcing, characterization, standardization, safety, and efficacy that need to be addressed for effective clinical use.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Beverly Brooks, Dominique Ebedes, Ahsan Usmani, Joaquin Vega Gonzales-Portillo, Daniel Gonzales-Portillo, Cesario Borlongan
Summary: Ischemic brain injury is a major cause of death worldwide with limited treatment options. Stem cell-based regenerative therapies, specifically mesenchymal stromal cells, show promise in stroke treatment, but further research is needed to fully understand their cell function.
Review
Immunology
Eliana Lara-Barba, Maria Jesus Araya, Charlotte Nicole Hill, Felipe A. Bustamante-Barrientos, Alexander Ortloff, Cynthia Garcia, Felipe Galvez-Jiron, Carolina Pradenas, Noymar Luque-Campos, Gabriela Maita, Roberto Elizondo-Vega, Farida Djouad, Ana Maria Vega-Letter, Patricia Luz-Crawford
Summary: The study discusses osteoarticular diseases and their treatment options, with a focus on cell therapy using MSCs and acellular therapy based on MSC secreted factors. It highlights the potential therapeutic impact of sEVs derived from MSCs and their miRNA cargo on target cells associated with the pathology of RA and OA.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Paula Laranjeira, Monia Pedrosa, Catia Duarte, Susana Pedreiro, Brigida Antunes, Tania Ribeiro, Francisco dos Santos, Antonio Martinho, Margarida Fardilha, M. Rosario Domingues, Manuel Abecasis, Jose Antonio Pereira da Silva, Artur Paiva
Summary: This study found that BM-MSC effectively reduced TNF-alpha, CD83, CCR7, and MIP-1 beta protein levels in mDCs and all monocyte subsets in RA patients. BM-MSC exhibited a suppressive action over antigen-presenting cells from RA patients, potentially affecting their ability to stimulate the immune adaptive response at different levels.
Article
Cell & Tissue Engineering
Eun Wha Choi, I. -Rang Lim, Ji Hong Park, Jiwoo Song, Bongkum Choi, Sungjoo Kim
Summary: Exosomes derived from disease-condition-serum-primed iMSCs showed potential in ameliorating cartilage damage in a RA model by enhancing TGF-beta 1 production, inducing Th2 and M2 polarization, and lowering proinflammatory cytokines levels. Patient-derived serum could be a valuable priming strategy for iMSC-derived exosome treatment of RA.
STEM CELL RESEARCH & THERAPY
(2023)
Review
Rheumatology
Giuliana Minani Bertolino, Marie Maumus, Christian Jorgensen, Daniele Noel
Summary: The incidence of rheumatic diseases is expected to increase due to population aging and increased physical activities among younger individuals, requiring curative strategies in addition to pain management. Mesenchymal stromal cells (MSCs) have regenerative potential due to the secretion of paracrine factors, many of which are encapsulated in extracellular vesicles (EVs) that mimic the functions of parental cells. MSC-derived EVs have anti-inflammatory, anti-apoptotic, and pro-regenerative properties, making them a promising cell-free therapy for rheumatic diseases.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Review
Immunology
Zhengping Che, Ziyu Ye, Xueying Zhang, Bihua Lin, Weiqing Yang, Yanfang Liang, Jincheng Zeng
Summary: Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory disorders of the gastrointestinal tract. Current treatments are not fully curative and often lead to relapse. Mesenchymal stem/stromal cells (MSCs), with their multipotent differentiation and immunomodulatory capabilities, show potential for the treatment of IBDs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Meryem Ouzin, Gesine Kogler
Summary: Mesenchymal stromal cells are widely used in regenerative medicine and translational research, but their heterogeneity and the lack of understanding of their molecular mechanisms pose challenges for clinical applications. This review focuses on the heterogeneity aspects related to tissue source and developmental origin, emphasizing the importance of generating homogeneous products for clinical use.
Review
Immunology
Jehan J. El-Jawhari, Yasser El-Sherbiny, Dennis McGonagle, Elena Jones
Summary: The pathogenesis of autoimmune rheumatological diseases such as RA and SLE is complex, involving various immune cell populations. MSCs may play a dual role in RA and SLE, having both pro-inflammatory effects and immunomodulatory potential. Although safety and proof of concept studies exist, robust phase 3 clinical trial data in therapy-resistant RA and SLE is still lacking.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Natalie Vallant, Bynvant Sandhu, Karim Hamaoui, Maria Prendecki, Charles Pusey, Vassilios Papalois
Summary: This study compared the paracrine effects of MSC supernatants from different age and genotype sources on macrophages, revealing distinct patterns of inflammatory marker expression. These findings are crucial for preclinical and clinical studies utilizing MSCs for inflammation and allo-response mitigation in transplant patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Health Care Sciences & Services
Mariangela Manfredi, Lieve Van Hoovels, Maurizio Benucci, Riccardo De Luca, Carmela Coccia, Pamela Bernardini, Edda Russo, Amedeo Amedei, Serena Guiducci, Valentina Grossi, Xavier Bossuyt, Carlo Perricone, Maria Infantino
Summary: uPAR is a membrane-bound glycoprotein, and its bioactive form, suPAR, is primarily expressed on the surface of immunologically active cells. Higher levels of suPAR have been associated with disease severity, relapse, and mortality in various inflammatory diseases. This review summarizes the current literature on the potential role of suPAR as a biomarker in autoimmune rheumatic and non-rheumatic diseases.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Immunology
Ayman F. Refaie, Batoul L. Elbassiouny, Malgorzata Kloc, Omaima M. Sabek, Sherry M. Khater, Amani M. Ismail, Rania H. Mohamed, Mohamed A. Ghoneim
Summary: MSC-based therapy for T1DM shows promise, but there are conflicting views on their immunological profile. Research focuses on understanding the mechanisms of their immunomodulatory functions and exploring ways to enhance their effects.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell Biology
Maria I. Quinones-Vico, Raquel Sanabria de la Torre, Manuel Sanchez-Diaz, Alvaro Sierra-Sanchez, Trinidad Montero-Vilchez, Ana Fernandez-Gonzalez, Salvador Arias-Santiago
Summary: The skin, the largest organ of the human body, has important functions including protection and maintenance. MSCs and their secretome, particularly exosomes, are believed to play a significant role in skin repair and regeneration, indicating the need for further research for clinical translation.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Immunology
Huldani Huldani, Saade Abdalkareem Jasim, Dmitry Olegovich Bokov, Walid Kamal Abdelbasset, Mohammed Nader Shalaby, Lakshmi Thangavelu, Ria Margiana, Maytham T. Qasim
Summary: Mesenchymal stem cells (MSCs) have great potential as therapeutic candidates, but their clinical application is limited due to their tumorigenic properties. Extracellular vesicles (EVs), as paracrine factors of MSCs, have gained attention as potential cell-free replacement therapy due to their low immunogenicity and tumorigenicity, as well as easy management.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)